• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva rises on mixed-bag Q4, sets 2022 guidance

February 9, 2022 By Sean Whooley

TevaTeva Pharmaceuticals (NYSE:TEVA) shares ticked up this morning on fourth-quarter results that topped the consensus EPS forecast.

The Tel Aviv, Israel–based company posted losses of $159 million, or 14¢ per share, on sales of $4.1 billion for the three months ended Dec. 31, 2021, for a bottom-line slide into the red on a sales decline of 7.9%.

Adjusted to exclude one-time items, earnings per share were 77¢, 4¢ ahead of Wall Street, where analysts were looking for sales of $4.3 billion.

“In 2021 Teva delivered solid results, generating strong cash flow and improving our profitability,” Teva President and CEO Kåre Schultz said in a news release. “While COVID-19 continued to impact patient behavior and global prescribing patterns, we continued to optimize our supply chain and manufacturing capabilities to provide essential medicines to the millions of patients who rely on us throughout the world. We improved our gross and operating margin and reduced our net debt, keeping us on our path to achieve our 2023 long-term goals.”

Teva said it expects to log adjusted EPS of between $2.40 and $2.60 and set its sales guidance for between $15.6 billion and $16.2 billion.

TEVA shares were up 8% at $8.95 just after the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.8%.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS